Sangamo Therapeutics (SGMOQ) Capital Expenditures (2010 - 2025)

Sangamo Therapeutics has reported Capital Expenditures for 16 years, with the latest figure at $14000.0 in Q4 2025.

• On a quarterly basis, Capital Expenditures rose 111.48% year-over-year to $14000.0 in Q4 2025; TTM through Dec 2025 was $102000.0, a 61.8% decrease from a year earlier, with the FY2025 full-year figure at $102000.0, down 61.8% from the prior year.
• Capital Expenditures was $14000.0 for Q4 2025 at Sangamo Therapeutics, up from -$13000.0 in the prior quarter.
• The five-year high for Capital Expenditures was $10.2 million in Q1 2023, with the low at -$133000.0 in Q2 2025.
• Average Capital Expenditures over 5 years is $3.2 million, with a median of $2.8 million recorded in 2022.
• The sharpest annual moves came in 2023 and 2025: Capital Expenditures soared 259.28% in 2023, then plunged 392.59% in 2025.
• Over 5 years, Capital Expenditures stood at $2.9 million in 2021, then surged by 161.51% to $7.5 million in 2022, then sank by 64.26% to $2.7 million in 2023, then sank by 104.57% to -$122000.0 in 2024, then jumped by 111.48% to $14000.0 in 2025.
• The last three Capital Expenditures figures came in at $14000.0 (Q4 2025), -$13000.0 (Q3 2025), and -$133000.0 (Q2 2025), per Business Quant data.